Objectives: This meta-analysis was to assess solifenacin and tolterodine in patients with overactive bladder. Methods: We searched PubMed, the Cochrane Library, EMBASE, CNKI, Wanfang, and ClinicalTrials.gov databases for randomized controlled trials (RCTs). The efficacy endpoint was daily micturition frequency, daily urgency episodes, daily incontinence episodes, and micturition volume per voiding. The safety endpoint was the incidence of the rate of major bleeding, intracranial bleeding, and gastrointestinal bleeding. Results: Seven RCTs met the inclusion criteria and 1,318 patients were included. The meta-analysis showed that, compared with tolterodine, solifenacin was associated with similar daily micturition frequency, daily urgency episodes, daily incontinence episode, and micturition volume per voiding at 8 and 12 weeks of follow-up. Moreover, no significant difference was obtained in the incidence of dry mouth between solifenacin and tolterodine at 8 and 12 weeks of follow-up. However, tolterodine decreased the constipation rate at 12 weeks compared with solifenacin. Conclusion: Solifenacin and tolterodine yielded similar results on daily micturition frequency, daily urgency episodes, daily incontinence episodes, micturition volume per voiding, and the incidence of dry mouth. However, tolterodine can decrease the constipation rate at 12 weeks compared with solifenacin.

Keywords:
Solifenacin, Tolterodine, Overactive bladder, Meta-analysis, First-line therapies
1.
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al.; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.
Neurourol Urodyn
. 2010;29(1):4–20.
2.
Martínez Agulló E, Ruíz Cerdá JL, Gómez Pérez L, Rebollo P, Pérez M, Chaves J. [Impact of urinary incontinence and overactive bladder syndrome on health-related quality of life of working middle-aged patients and institutionalized elderly patients].
Actas Urol Esp
. 2010 Mar;34(3):242–50.
3.
Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.
Res Rep Urol
. 2013 Dec;6:1–16.
4.
Lee KS, Na YG, Dean-McKinney T, Klausner AP, Tuttle JB, Steers WD. Alterations in voiding frequency and cystometry in the clomipramine induced model of endogenous depression and reversal with fluoxetine.
J Urol
. 2003 Nov;170(5):2067–71.
5.
Di Rezze S, Frasca V, Inghilleri M, Durastanti V, Cortese A, Giacomelli E, et al. Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study. Clin Neuropharmacol. 2012 Sep-Oct;35(5):231–4.
6.
Swinburn P, Lloyd A, Ali S, Hashmi N, Newal D, Najib H. Preferences for antimuscarinic therapy for overactive bladder.
BJU Int
. 2011 Sep;108(6):868–73.
7.
Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen CI, Markland A. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study.
J Am Geriatr Soc
. 2011 Aug;59(8):1465–70.
8.
Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, et al.; SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
BJU Int
. 2008 Nov;102(9):1120–7.
9.
Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, et al.; STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
Eur Urol
. 2005 Sep;48(3):464–70.
10.
Walther S, Schuetz GM, Hamm B, Dewey M. [Quality of reporting of systematic reviews and meta-analyses: PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses)].
RoFo Fortschr Geb Rontgenstr Nuklearmed
. 2011 Dec;183(12):1106–10.
11.
Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al.; YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
BJU Int
. 2004 Feb;93(3):303–10.
12.
Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, et al. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.
Int J Clin Pract
. 2008 Nov;62(11):1675–83.
13.
Ho CH, Chang TC, Lin HH, Liu SP, Huang KH, Yu HJ. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
J Formos Med Assoc
. 2010 Oct;109(10):702–8.
14.
Hsiao SM, Chang TC, Wu WY, Chen CH, Yu HJ, Lin HH. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
J Obstet Gynaecol Res
. 2011 Aug;37(8):1084–91.
15.
Tan Y, Xiong T. Efficacy and safety of solifenac in treating of overactive bladder.
Xiandai Yiyao Weisheng
. 2011;(05):657–8.
16.
Wu S, Xiao Y, Duan J, Ding Q, Sun Y, Huang Y, et al. Efficacy and safety of solifenacin in the treatment of patients with urgency and urge incontinence.
Chinese Joural of Urology.
2009;30(9):630–4.
17.
Xia H, Zheng J, Xiong T. The efficacy and safety of solifenacin vesicare therapy in patients with overactive bladder. Chinese Journal of Clinical Research. 2011;8:671–3.
18.
Xu K, Wang J. Status and Prospect of Overactive Bladder.
Chinese Journal of Urology.
2012;33(9):708–10.
19.
Song B. The role of bladder original excitation dysfunction in overactive bladder.
Zhonghua Yi Xue Za Zhi
. 2013 Nov 12;93(42):3329–30.
20.
Liu B, Li P, Li J, Wang Y, Wu Y. [Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes].
Zhonghua Yi Xue Za Zhi
. 2014 Aug;94(30):2350–4.
21.
Xu C, Jiang XZ, Zhang NZ, Zhao HF, Xu ZS. [Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis].
Zhonghua Yi Xue Za Zhi
. 2012 Dec;92(48):3398–402.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.